Diversified Trust Co Increases Holdings in Novo Nordisk A/S (NYSE:NVO)

Diversified Trust Co increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 13.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,246 shares of the company’s stock after purchasing an additional 395 shares during the quarter. Diversified Trust Co’s holdings in Novo Nordisk A/S were worth $279,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. International Assets Investment Management LLC grew its holdings in Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after buying an additional 1,796,635 shares in the last quarter. DSM Capital Partners LLC boosted its position in shares of Novo Nordisk A/S by 257,816.0% during the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after acquiring an additional 1,593,303 shares during the last quarter. Mediolanum International Funds Ltd bought a new stake in Novo Nordisk A/S in the 3rd quarter valued at $98,765,000. Marshall Wace LLP lifted its stake in Novo Nordisk A/S by 34,472.1% in the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after purchasing an additional 689,441 shares in the last quarter. Finally, Wellington Management Group LLP bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at about $42,017,000. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the topic of several research reports. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $86.41 on Friday. The firm has a market capitalization of $387.77 billion, a PE ratio of 27.96, a PEG ratio of 1.37 and a beta of 0.45. The stock’s fifty day moving average is $100.35 and its 200 day moving average is $119.21. Novo Nordisk A/S has a fifty-two week low of $81.50 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.